About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals is a company based in Vancouver (Canada) founded in 2012 by James Helliwell. Eupraxia Pharmaceuticals has raised $2.44 million across 10 funding rounds from investors including SVB and National Research Council Canada. Eupraxia Pharmaceuticals operates in a competitive market with competitors including Formation Bio, Flexion Therapeutics, MRM Health, TissueGene and Symic Biomedical, among others.
- Headquarter Vancouver, Canada
- Founders James Helliwell
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Eupraxia Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$24.28 M (USD)8.27as on Dec 31, 2024
-
EBITDA
-$25.55 M (USD)2.44as on Dec 31, 2024
-
Total Equity Funding
$2.44 M (USD)
in 10 rounds
-
Latest Funding Round
$32 M (USD), Post-IPO
Oct 31, 2024
-
Investors
SVB
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals is a publicly listed company on the TSX with ticker symbol EPRX in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals has successfully raised a total of $2.44M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $32 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include SVB and National Research Council Canada.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Scientific and technological research is conducted for Canada's benefit.
|
Locked | Locked | Locked | |
|
Banking services are provided to innovative companies, investors, and individuals.
|
Locked | Locked | Locked |
Investor details for Eupraxia Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eupraxia Pharmaceuticals
Investment portfolio details for Eupraxia Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Eupraxia Pharmaceuticals
Detailed financials for Eupraxia Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eupraxia Pharmaceuticals Comparisons
Peer comparison for Eupraxia Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Formation Bio, Flexion Therapeutics, MRM Health, TissueGene and Symic Biomedical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-powered drug discovery platform for various diseases
|
|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Developer of optimized consortia therapeutics targeting inflammatory, CNS, and metabolic diseases
|
|
| Locked | Locked | Locked |
Regenerative cell therapies for orthopedic diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of compounds to protect against tissue degradation and promote healing during illness or injury
|
Detailed competitors of Eupraxia Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eupraxia Pharmaceuticals
Complete news archive for Eupraxia Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals was founded in 2012.
Eupraxia Pharmaceuticals is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
James Helliwell is the current CEO of Eupraxia Pharmaceuticals. They have also founded this company.
Eupraxia Pharmaceuticals is a funded company, having raised a total of $2.44M across 10 funding rounds to date.
Eupraxia Pharmaceuticals is a pharmaceutical company that has a proprietary drug delivery platform. The technology encapsulates pharmaceutical microparticles in a customizable polymer shell that can extend drug release from days to months. The company works on the existing drugs and uses its injectable drug delivery platform for targeted therapies. It also has preclinical and development phase candidates for chronic pain, anesthesia, diabetic macular edema, and infections. The companys lead product candidate, EP-104IAR (phase I clinical trial) is a sustained-release product of the anti-inflammatory, fluticasone propionate for pain relief for patients with osteoarthritis. It also has a phase 1 candidate for veterinary health. In 2016, the company has entered into a license agreement with Auritec under which Eupraxia licensed the Plexis platform technology and intellectual property rights from Auritec for the sustained delivery of corticosteroids.
Eupraxia Pharmaceuticals's top competitors include Flexion Therapeutics, Formation Bio and ARTHEx.
Yes, Eupraxia Pharmaceuticals is publicly traded on TSX under the ticker symbol EPRX.
Eupraxia Pharmaceuticals has 2 investors. Key investors include SVB, and National Research Council Canada.
The ticker symbol of Eupraxia Pharmaceuticals is EPRX on TSX.